intracellular sigma peptide INTRACELLULAR SIGMA PEPTIDE - PAP4peptide Intracellular sigma peptide Intracellular Sigma Peptide: A Promising Avenue for Nervous System Repair

PAP4peptidefor sale Intracellular sigma peptide (ISP) is a synthetic peptide that has emerged as a significant area of research for its potential to promote nervous system repair. This peptide acts as a mimetic of the "wedge" domain of protein tyrosine phosphatase sigma (PTPσ), a neural receptor implicated in the inhibition of nerve regenerationInhibition of CSPG receptor PTPσ promotes migration .... By targeting and modulating PTPσ signaling, ISP shows promise in overcoming the cellular barriers that impede recovery after injury or disease. Research into ISP, and related compounds like NVG-291, highlights its potential applications in conditions such as spinal cord injury, stroke, and demyelinating diseases.

Understanding Protein Tyrosine Phosphatase Sigma (PTPσ)

Protein tyrosine phosphatase sigma (PTPσ) is a transmembrane receptor protein that plays a crucial role in the central nervous system. It is particularly known for its interaction with chondroitin sulfate proteoglycans (CSPGs), which are abundant in the extracellular matrix of the central nervous system and can inhibit neuronal growth and regeneration.Compound shows 'extraordinary' promise in restoring ... PTPσ's "wedge" domain is critical for its function in signaling pathways that influence neuronal plasticity and repair. When PTPσ is overactive or improperly regulated, it can contribute to the inhibitory environment that prevents damaged neurons from regrowing and reconnecting.

The Mechanism of Action for Intracellular Sigma Peptide

Intracellular sigma peptide (ISP) is designed to specifically interact with the wedge domain of PTPσ. As a membrane-permeable peptide, ISP can enter cells and bind to PTPσ, effectively disrupting its normal function. This disruption can lead to several beneficial outcomes:

* Inhibition of CSPG Signaling: By interfering with PTPσ's interaction with CSPGs, ISP can alleviate the inhibitory signals that normally prevent nerve regeneration.

* Promotion of Remyelination: Studies suggest that modulating PTPσ activity with ISP can improve remyelination, a critical process for restoring nerve function after demyelinating injuries.

* Enhanced Neuronal Survival and Growth: By reducing the inhibitory environment, ISP may create conditions more conducive to neuronal survival, axon growth, and the formation of new synaptic connections.

* Functional Recovery: Preclinical studies have demonstrated that ISP can lead to significant improvements in motor function and recovery after various types of nervous system injuriesEmpowering the nervous system to repair itself.

Applications and Research Findings

The potential applications of intracellular sigma peptide are broad, with a significant focus on neurological conditions that involve damage to the central nervous system.

* Spinal Cord Injury: Several studies have investigated ISP's efficacy in animal models of spinal cord injury. In these models, ISP administration has been shown to promote nerve regeneration, reduce glial scarring, and restore motor function, allowing paralyzed muscles to activate.多肽研发公司

* Demyelinating Diseases: Research has explored ISP's role in conditions like multiple sclerosis, where the myelin sheath surrounding nerve fibers is damaged.ChemicalBook 致力于为化学行业用户提供的性质、化学式、分子式、比重、密度,同时也包括的沸点、熔点、MSDS、用途、作用、毒性、价格、生产厂家、用途、上游原料、下游 ... ISP has demonstrated the ability to improve remyelination and functional recovery in mice with induced demyelination在线留言英文名称ISPpeptide(INTRACELLULAR SIGMA PEPTIDE) 中文名称CAS NO 货号603639 序列GRKKRRQRRRCDMAEHMERLKANDSLKLSQEYESI-NH2 分子式C177H306N66O54S3 ....

* Stroke and Neurodegenerative Diseases: While research is ongoing, the ability of ISP to promote neuronal repair and overcome inhibitory signaling pathways suggests potential benefits for conditions like stroke, where neuronal loss and impaired connectivity are central problemsDrug found to help repair spinal cord injuries.

* Related Compounds: The development of ISP has paved the way for related therapeutic candidatesDrug found to help repair spinal cord injuries. NVG-291, for instance, is a drug candidate developed by NervGen Pharma that is structurally similar to ISP and targets PTPσ. TAT-ISP, a cell-penetrating variant of ISP, has also been developed to enhance cellular uptake and therapeutic effect.

Future Directions and Considerations

The preclinical data surrounding intracellular sigma peptide is highly encouraging, pointing towards a novel therapeutic strategy for a range of debilitating neurological conditions. Further research is crucial to fully elucidate its mechanisms of action, optimize delivery methods, and confirm its safety and efficacy in human clinical trials. The development of ISP represents a significant step forward in understanding and potentially reversing the damage caused by injuries and diseases affecting the nervous system, offering a new beacon of hope for patients and researchers alike.